Proton vs. photon radiotherapy for MR-guided dose escalation of intraprostatic lesions

References

• Artibani W, Porcaro AB, De Marco V, et al. Management of biochemical recurrence after primary curative treatment for prostate cancer: a review. Urol Int. 2018;100(3):251–262.
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433–439.
   PubMed Web of Science ®Google Scholar
• Kupelian PA, Mahadevan A, Reddy CA, et al. Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer. Urology. 2006;68(3):593–598.
   PubMed Web of Science ®Google Scholar
• Heemsbergen WD, Al-Mamgani A, Slot A, et al. Long-term results of the Dutch randomized prostate cancer trial: impact of dose- escalation on local, biochemical, clinical failure, and survival. Radiother Oncol. 2014;110(1):104–109.
   PubMed Web of Science ®Google Scholar
• Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294(10):1233–1239.
   PubMed Web of Science ®Google Scholar
• Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24(13):1990–1996.
   PubMed Web of Science ®Google Scholar
• Dearnaley DP, Jovic G, Syndikus I, et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2014;15(4):464–473.
   PubMed Web of Science ®Google Scholar
• Beckendorf V, Guerif S, Le PE, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys. 2011;80(4):1056–1063.
   PubMed Web of Science ®Google Scholar
• Reinsberg SA, Payne GS, Riches SF, et al. Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection. Am J Roentgenol. 2007;188(1):91–98.
   PubMed Web of Science ®Google Scholar
• Margolis DJA. Multiparametric MRI for localized prostate cancer: lesion detection and staging. Biomed Res Int. 2014;2014:684127.
   PubMed Web of Science ®Google Scholar
• de Rooij M, Hamoen EHJ, FüTterer JJ, et al. Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. Am J Roentgenol. 2014;202(2):343–351.
   PubMed Web of Science ®Google Scholar
• Chamie K, Sonn GA, Finley DS, et al. The role of magnetic resonance imaging in delineating clinically significant prostate cancer. Urol. 2014;83(2):369–375.
   PubMed Web of Science ®Google Scholar
• Itatani R, Namimoto T, Atsuji S, et al. Negative predictive value of multiparametric MRI for prostate cancer detection: outcome of 5-year follow-up in men with negative findings on initial MRI studies. Eur J Radiol. 2014;83(10):1740–1745.
   PubMed Web of Science ®Google Scholar
• Goodman CD, Fakir H, Pautler S, et al. Dosimetric evaluation of PSMA PET-delineated dominant intraprostatic lesion simultaneous infield boosts. Adv Radiat Oncol. 2020;5(2):212–220.
   PubMedGoogle Scholar
• De Meerleer G, Villeirs G, Bral S, et al. The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapy. Radiother Oncol. 2005;75(3):325–333.
   PubMed Web of Science ®Google Scholar
• Singh AK, Guion P, Sears-Crouse N, et al. Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study. Radiat Oncol. 2007;2:36.
   PubMed Web of Science ®Google Scholar
• Fonteyne V, Villeirs G, Speleers B, et al. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys. 2008;72(3):799–807.
   PubMed Web of Science ®Google Scholar
• Lips IM, van der Heide UA, Haustermans K, et al. Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial. Trials. 2011;12:255.
   PubMed Web of Science ®Google Scholar
• Monninkhof EM, van Loon JWL, van Vulpen M, et al. Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: toxicity in the FLAME randomized controlled trial. Radiother Oncol. 2018;127(1):74–80.
   PubMed Web of Science ®Google Scholar
• Murray JR, Tree AC, Alexander EJ, et al. Standard and hypofractionated dose escalation to intraprostatic tumor nodules in localized prostate cancer: efficacy and toxicity in the DELINEATE Trial. Int J Radiat Oncol Biol Phys. 2020;106(4):715–724.
   PubMed Web of Science ®Google Scholar
• Miralbell R, Mollà M, Rouzaud M, et al. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study. Int J Radiat Oncol Biol Phys. 2010;78(1):50–57.
   PubMed Web of Science ®Google Scholar
• Onjukka E, Uzan J, Baker C, et al. Twenty fraction prostate radiotherapy with intra-prostatic boost: results of a pilot study. Clin Oncol. 2017;29(1):6–14.
   Web of Science ®Google Scholar
• Syndikus I, Cruickshank C, Staffurth J, et al. PIVOTALboost: a phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK/16/018). Clin Transl Radiat Oncol. 2020;25:22–28.
   PubMed Web of Science ®Google Scholar
• Sharp GC, Lui R, Wolfgang J, et al. Plastimatch an open source software suite for radiotherapy image processing. Proc. 16th Int. Conf. on the Use of Computers in Radiotherapy (ICCR), Amsterdam; 2010.
   Google Scholar
• Riches SF, Payne GS, Desouza NM, et al. Effect on therapeutic ratio of planning a boosted radiotherapy dose to the dominant intraprostatic tumour lesion within the prostate based on multifunctional MR parameters. Br J Radiol. 2014;87(1037):20130813.
   PubMed Web of Science ®Google Scholar
• Alexander EJ, Murray JR, Morgan VA, et al. Validation of T2- and diffusion-weighted magnetic resonance imaging for mapping intra-prostatic tumour prior to focal boost dose-escalation using intensity-modulated radiotherapy (IMRT). Radiother Oncol. 2019;141:181–187.
   PubMed Web of Science ®Google Scholar
• Astroid- Proton Planning System. Available from: https://protontps.com/astroid/
   Google Scholar
• Kooy HM, Clasie BM, Lu HM, et al. A case study in proton pencil-beam scanning delivery. Int J Radiat Oncol Biol Phys. 2010;76(2):624–630.
   PubMed Web of Science ®Google Scholar
• Clasie B, Depauw N, Fransen M, et al. Golden beam data for proton pencil-beam scanning. Phys Med Biol. 2012;57(5):1147–1158.
   PubMed Web of Science ®Google Scholar
• Efstathiou JA. Proton therapy versus IMRT for low or intermediate risk prostate cancer (PARTIQoL). 2012 [Updated 2018 Jan 9; cited 2019 Nov 8]. Available from: https://clinicaltrials.gov/ct2/show/.
   Google Scholar
• Niemierko A. A generalized concept of Equivalent Uniform Dose (EUD). Med Phys. 1999;26:1100.
   Google Scholar
• Li XA, Alber M, Deasy JO, et al. The use and QA of biologically related models for treatment planning: short report of the TG-166 of the therapy physics committee of the AAPM. Med Phys. 2012;39(3):1386–1409.
   PubMed Web of Science ®Google Scholar
• Kim Y, Tomé WA. Is it beneficial to selectively boost high-risk tumor subvolumes? A comparison of selectively boosting high-risk tumor subvolumes versus homogeneous dose escalation of the entire tumor based on equivalent EUD plans. Acta Oncol. 2008;47(5):906–916.
   PubMed Web of Science ®Google Scholar
• Azzeroni R, Maggio A, Fiorino C, et al. Biological optimization of simultaneous boost on intra-prostatic lesions (DILs): sensitivity to TCP parameters. Phys Med. 2013;29(6):592–598.
   PubMed Web of Science ®Google Scholar
• Murray LJ, Lilley J, Thompson CM, et al. Prostate stereotactic ablative radiation therapy using volumetric modulated arc therapy to dominant intraprostatic lesions. Int J Radiat Oncol Biol Phys. 2014;89(2):406–415.
   PubMed Web of Science ®Google Scholar
• Wang T, Zhou J, Tian S, et al. A planning study of focal dose escalations to multiparametric MRI-defined dominant intraprostatic lesions in prostate proton radiation therapy. Br J Radiol. 2020;93(1107):20190845.
   PubMed Web of Science ®Google Scholar
• Pedersen J, Casares-Magaz O, Petersen JBB, et al. A biological modelling based comparison of radiotherapy plan robustness using photons vs protons for focal prostate boosting. Phys Imaging Radiat Oncol. 2018;6:101–105.
   PubMedGoogle Scholar
• Andrzejewski P, Kuess P, Knäusl B, et al. Feasibility of dominant intraprostatic lesion boosting using advanced photon-, proton- or brachytherapy. Radiother Oncol. 2015;117(3):509–514.
   PubMed Web of Science ®Google Scholar
• Yeo I, Nookala P, Gordon I, et al. Passive proton therapy vs. IMRT planning study with focal boost for prostate cancer. Radiat Oncol. 2015;10:213.
   PubMed Web of Science ®Google Scholar
• Fellin F, Azzeroni R, Maggio A, et al. Helical tomotherapy and intensity modulated proton therapy in the treatment of dominant intraprostatic lesion: a treatment planning comparison. Radiother Oncol. 2013;107(2):207–212.
   PubMed Web of Science ®Google Scholar
• Van Loon J, Van Vulpen M, Pos F, et al. FLAME: influence of dose escalation to 95Gy for prostate cancer on urethra-related toxicity and QOL. Radiother Oncol. 2016;119:S24.
   Web of Science ®Google Scholar
• Vanneste BGL, Buettner F, Pinkawa M, et al. Ano-rectal wall dose-surface maps localize the dosimetric benefit of hydrogel rectum spacers in prostate cancer radiotherapy. Clin Transl Radiat Oncol. 2019;14:17–24.
   PubMed Web of Science ®Google Scholar
• King RB, Osman SO, Fairmichael C, et al. Efficacy of a rectal spacer with prostate SABR-first UK experience. Br J Radiol. 2018;91(1083):20170672.
   PubMed Web of Science ®Google Scholar
• Moteabbed M, Trofimov A, Sharp GC, et al. Proton therapy of prostate cancer by anterior-oblique beams: implications of setup and anatomy variations. Phys Med Biol. 2017;62(5):1644–1960.
   PubMed Web of Science ®Google Scholar
• Underwood T, Giantsoudi D, Moteabbed M, et al. Can we advance proton therapy for prostate? Considering alternative beam angles and relative biological effectiveness variations when comparing against intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2016;95(1):454–464.
   PubMed Web of Science ®Google Scholar
• Ciardo D, Jereczek-Fossa B, Petralia G, et al. Multimodal image registration for the identification of dominant intraprostatic lesion in high-precision radiotherapy treatments. Br J Radiol. 2017;90(1079):20170021.
   PubMed Web of Science ®Google Scholar